Protagenic Therapeutics, Inc.\new (PTIX) Return on equity 2022–2026
Protagenic Therapeutics, Inc.\new (PTIX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
52.2%FY2026 · since FY2022: -45.5% → 52.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | 52.2% | — |
| FY2024 | -136.3% | -84.9 pp |
| FY2023 | -51.4% | -5.9 pp |
| FY2022 | -45.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More PTIX financial trends
PTIX RevenuePTIX Net incomePTIX Net marginPTIX Gross profitPTIX Gross marginPTIX Operating incomePTIX Operating marginPTIX Operating cash flowPTIX Free cash flowPTIX Capital expendituresPTIX Stock buybacksPTIX Dividends paidPTIX Total assetsPTIX Total liabilitiesPTIX Shareholders’ equityPTIX overview →